Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Sarcoma 5Sarcoma, Kaposi 4Unspecified Adult Solid Tumor, Protocol Specific 3Skin Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Prostatic Neoplasms 2Head and Neck Neoplasms 2HIV Infections 2Colonic Neoplasms 2AIDS-related Kaposi sarcoma 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solitary Fibrous Tumor, Pleural 1Salivary Gland Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms, Unknown Primary 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Meningioma 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Inflammatory Breast Neoplasms 1

Interventions

Cytarabine 272Cyclophosphamide 136fludarabine phosphate 127Azacitidine 117Peripheral Blood Stem Cell Transplantation 95Busulfan 93Filgrastim 80Decitabine 79fludarabine 78Mycophenolic Acid 78Idarubicin 76Etoposide 76Whole-Body Irradiation 75Daunorubicin 72Tacrolimus 71Cyclosporine 64Methotrexate 62Mitoxantrone 57Clofarabine 55Antilymphocyte Serum 55Granulocyte Colony-Stimulating Factor 51Gemtuzumab 50Melphalan 49venetoclax 48Radiotherapy 30sargramostim 28Injections 25Bortezomib 25thymoglobulin 24aldesleukin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid, Acute × Semaxinib × Clear all
NCT00005942 2013-01-23

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

National Cancer Institute (NCI)

Phase 1/2 Completed
37 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡